Citius Pharmaceuticals Grabs $3.8 Million from New Jersey's Economic Development Initiative Citius Pharmaceuticals has successfully obtained $3.8 million in non-dilutive capital from New Jersey's Economic Development Program, reinforcing its financial strength.

Citius Pharmaceuticals Grabs $3.8 Million from New Jersey's Economic Development Initiative #United_States #New_Jersey #Cranford #Citius_Pharmaceuticals #NOL_Program

Citius Pharmaceuticals Reports First Revenue from LYMPHIR Launch: A New Conquest in Oncology Citius Pharmaceuticals marks a significant milestone by announcing its first revenue from the newly launched LYMPHIR. This development points to a successful foothold in oncology, aiming to bring hope to patients.

Citius Pharmaceuticals Reports First Revenue from LYMPHIR Launch: A New Conquest in Oncology #United_States #Cranford #oncology #Citius_Pharmaceuticals #LYMPHIR

Citius Pharmaceuticals Completes $6 Million Direct Offering to Fuel Growth Citius Pharmaceuticals has successfully finalized a direct offering worth $6 million. The proceeds will propel the launch of its innovative product, LYMPHIR, and further its development initiatives.

Citius Pharmaceuticals Completes $6 Million Direct Offering to Fuel Growth #United_States #Cranford #Citius_Pharmaceuticals #LYMPHIR #Nasdaq_CTXR

Citius Pharmaceuticals Initiates $6 Million Direct Share Offering Under Nasdaq Regulations Citius Pharmaceuticals announces a registered direct offering worth $6 million under Nasdaq regulations, aimed at supporting product development.

Citius Pharmaceuticals Initiates $6 Million Direct Share Offering Under Nasdaq Regulations #United_States #Cranford #Citius_Pharmaceuticals #Clinical_Trials #LYMPHIR

Citius Pharmaceuticals and Citius Oncology Engage in Investor Conferences This October 2025 Citius Pharmaceuticals and Citius Oncology are set to participate in key investor conferences in October 2025, showcasing their latest innovations.

Citius Pharmaceuticals and Citius Oncology Engage in Investor Conferences This October 2025 #United_States #New_York #Citius_Pharmaceuticals #LYMPHIR #Citius_Oncology

Citius Pharmaceuticals Reports Financial Results and Key Business Update for Q3 2025 Citius Pharmaceuticals, Inc. has announced its fiscal Q3 2025 financial results, highlighting significant advances in product commercialization and financial health.

Citius Pharmaceuticals Reports Financial Results and Key Business Update for Q3 2025 #USA #Citius_Pharmaceuticals #Mino-Lok #LYMPHIR #Cranford,_N.J.

Citius Oncology Successfully Closes $9 Million Public Offering for LYMPHIR Commercialization Citius Oncology has completed a public offering, raising $9 million to advance its commercial efforts for the FDA-approved drug LYMPHIR. The funds will support its further development.

Citius Oncology Successfully Closes $9 Million Public Offering for LYMPHIR Commercialization #USA #Citius_Pharmaceuticals #LYMPHIR #Citius_Oncology #Cranford,_NJ

Citius Pharmaceuticals Meets Nasdaq's Minimum Bid Price Requirement and Maintains Listing Citius Pharmaceuticals has successfully met the Nasdaq minimum bid price requirement, maintaining its listing after a period of compliance. The company continues to focus on critical care product development.

Citius Pharmaceuticals Meets Nasdaq's Minimum Bid Price Requirement and Maintains Listing #United_States #NASDAQ #CTXR #Citius_Pharmaceuticals #Cranford,_New_Jersey

Citius Pharmaceuticals Completes $15.8 Million Registered Direct Offering for Oncology Product Development Citius Pharmaceuticals has successfully closed a registered direct offering, raising $15.8 million, to support the launch of its oncology treatment LYMPHIR™ and other pharmaceuticals.

Citius Pharmaceuticals Completes $15.8 Million Registered Direct Offering for Oncology Product Development #United_States #CTXR #Cranford #Citius_Pharmaceuticals #LYMPHIR

Citius Pharmaceuticals Reports Strong Financial Progress with FDA Approval on the Horizon Citius Pharmaceuticals shares financial updates and strategic plans, emphasizing their push towards the launch of LYMPHIR and enhanced market position.

Citius Pharmaceuticals Reports Strong Financial Progress with FDA Approval on the Horizon #United_States #CTXR #Cranford #Citius_Pharmaceuticals #LYMPHIR

Citius Pharmaceuticals Set to Showcase Innovations at Jefferies Global Healthcare Conference 2025 Citius Pharmaceuticals, along with Citius Oncology, will present pivotal advancements at the Jefferies Global Healthcare Conference this June.

Citius Pharmaceuticals Set to Showcase Innovations at Jefferies Global Healthcare Conference 2025 #USA #New_York #Citius_Pharmaceuticals #LYMPHIR #Citius_Oncology

Citius Pharmaceuticals' Q1 2025: Progress in Innovations and Financial Overview Citius Pharmaceuticals released its financial results for Q1 2025, showcasing advancements in clinical trials while revealing a net loss amidst strategic growth plans.

Citius Pharmaceuticals' Q1 2025: Progress in Innovations and Financial Overview #United_States #Cranford #financial_results #Citius_Pharmaceuticals #LYMPHIR

Citius Pharmaceuticals Secures $3 Million in Direct Offering Under Nasdaq Regulations Citius Pharmaceuticals has announced a pivotal $3 million registered direct offering, expanding its financial capabilities for product development and growth.

Citius Pharmaceuticals Secures $3 Million in Direct Offering Under Nasdaq Regulations #FDA_Approval #CTXR #Citius_Pharmaceuticals

Citius Pharmaceuticals Announces Launch Plans for LYMPHIR Immunotherapy in 2025 Citius Pharmaceuticals is set to launch LYMPHIR, an innovative immunotherapy for relapsed cutaneous T-cell lymphoma, in early 2025.

Citius Pharmaceuticals Announces Launch Plans for LYMPHIR Immunotherapy in 2025 #United_States #Cranford #Citius_Pharmaceuticals #LYMPHIR #Citius_Oncology

Citius Pharmaceuticals Reports Strong Financial Performance and Strategic Developments for Fiscal Year 2024 Citius Pharmaceuticals, Inc. has made significant strides in 2024, achieving FDA approval for its new immunotherapy product and enhancing its financial strategies for future growth.

Citius Pharmaceuticals Reports Strong Financial Performance and Strategic Developments for Fiscal Year 2024 #United_States #Citius_Pharmaceuticals #Mino-Lok #Cranford,_New_Jersey #LYMPHIR

Citius Pharmaceuticals Engages in Constructive FDA Meeting for Mino-Lok Approval Process Citius Pharmaceuticals reported a productive FDA meeting discussing the Phase 3 Mino-Lok program, paving the way for future approval.

Citius Pharmaceuticals Engages in Constructive FDA Meeting for Mino-Lok Approval Process #USA #FDA_Approval #Citius_Pharmaceuticals #Mino-Lok #Cranford,_New_Jersey